UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 125

Sortiert nach

PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms

American journal of hematology, 2022-04, Vol.97 (4), p.390-400

2022

Link zum Volltext

Verfügbarkeit prüfen

Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease

American journal of hematology, 2017-09, Vol.92 (9), p.885-891

2017

Link zum Volltext

Verfügbarkeit prüfen

Paraneoplastic autoimmune thrombocytopenia in solid tumors

Critical reviews in oncology/hematology, 2012-01, Vol.81 (1), p.75-81

2012

Link zum Volltext

Verfügbarkeit prüfen

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM

Cancers, 2021-11, Vol.13 (23), p.5886

2021

Link zum Volltext

Verfügbarkeit prüfen

Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers

Journal of cancer research and clinical oncology, 2021-01, Vol.147 (1), p.205-212

2021

Link zum Volltext

Verfügbarkeit prüfen

Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome

Hematology (Luxembourg), 2024-12, Vol.29 (1), p.2311600-2311600

2024

Link zum Volltext

Verfügbarkeit prüfen

Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact

British journal of haematology, 2014-03, Vol.164 (6), p.822-833

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study

BMC cancer, 2018-10, Vol.18 (1), p.1008-1008, Article 1008

2018

Link zum Volltext

Verfügbarkeit prüfen

Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily

Haematologica (Roma), 2011-01, Vol.96 (1), p.163-166

2011

Link zum Volltext

Verfügbarkeit prüfen

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

The lancet oncology, 2019-06, Vol.20 (6), p.781-794

2019

Link zum Volltext

Verfügbarkeit prüfen

Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia

Cancer research (Chicago, Ill.), 2004-05, Vol.64 (9), p.3148-3154

2004

Link zum Volltext

Verfügbarkeit prüfen

Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens

The Journal of immunology (1950), 2008-04, Vol.180 (8), p.5466-5476

2008

Link zum Volltext

Verfügbarkeit prüfen

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data

Blood cancer journal (New York), 2017-12, Vol.7 (12), p.643-4, Article 643

2017

Link zum Volltext

Verfügbarkeit prüfen

Detection of molecular targets on the surface of CD34+ CD38− stem cells in various myeloid malignancies

Leukemia & lymphoma, 2006-02, Vol.47 (2), p.207-222

2006

Link zum Volltext

Verfügbarkeit prüfen

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Blood, 2018-08, Vol.132 (7), p.694-706

2018

Link zum Volltext

Verfügbarkeit prüfen

Vaccination with genetically modified birch pollen allergens: Immune and clinical effects on oral allergy syndrome

Journal of allergy and clinical immunology, 2007-04, Vol.119 (4), p.1013-1016

2007

Link zum Volltext

Verfügbarkeit prüfen

Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab

Molecular oncology, 2010-04, Vol.4 (2), p.150-160

2010

Link zum Volltext

Verfügbarkeit prüfen

Monoclonal gammopathy of undetermined significance (MGUS): where is the hidden danger? Definition and work-up

Memo - Magazine of European medical oncology, 2021-03, Vol.14 (1), p.76-79

2021

Link zum Volltext

Verfügbarkeit prüfen

Pathway-Directed Therapy in Multiple Myeloma

Cancers, 2021-04, Vol.13 (7), p.1668

2021

Link zum Volltext

Verfügbarkeit prüfen

Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells

Blood, 2007-07, Vol.110 (2), p.661-669

2007

Link zum Volltext

Verfügbarkeit prüfen

Mast cell–derived proteases control allergic inflammation through cleavage of IgE

Journal of allergy and clinical immunology, 2008, Vol.121 (1), p.197-202

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 125

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(122)

Publikationsform

Sprache

Englisch
(122)
Japanisch
(12)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(61)
Science & Technology
(61)
Humans
(48)
Hematology
(31)
Oncology
(24)
Biological And Medical Sciences
(22)
Medical Sciences
(22)
Female
(21)
Male
(17)
Middle Aged
(17)
Adult
(16)
Aged
(13)
Multiple Myeloma
(13)
Hematologic And Hematopoietic Diseases
(12)
Immunology
(12)
Animals
(11)
Patients
(10)
Allergy
(9)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(9)
Mutation
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple myeloma

Phenotypic characterization of disease‐initiating stem cells in JAK2‐ or CALR‐mutated myeloproliferative neoplasms

Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease

Paraneoplastic autoimmune thrombocytopenia in solid tumors

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM

Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers

Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome

Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact

Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides

Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia

Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data

Detection of molecular targets on the surface of CD34+ CD38− stem cells in various myeloid malignancies

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Vaccination with genetically modified birch pollen allergens: Immune and clinical effects on oral allergy syndrome

Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab

Monoclonal gammopathy of undetermined significance (MGUS): where is the hidden danger? Definition and work-up

Pathway-Directed Therapy in Multiple Myeloma

Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells

Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells

Mast cell–derived proteases control allergic inflammation through cleavage of IgE

Suchergebnisse filtern